{"product_id":"pdl1-elisa-kit-for-human","title":"PDL1 ELISA kit (Human)","description":"\u003cp\u003e\u003cb\u003eSize\u003c\/b\u003e: 96Tests\u003c\/p\u003e\u003cp\u003e\u003cb\u003e# of Times Cited in literature\u003c\/b\u003e: 45\u003c\/p\u003e\u003cp\u003e\u003cb\u003ePrepare Time\u003c\/b\u003e: 1-3 days(please inquire for mutiple units)\u003c\/p\u003e\u003cp\u003e\u003cb\u003eTarget Name\u003c\/b\u003e: PDL1\u003c\/p\u003e\u003cp\u003e\u003cb\u003eTarget Full Name\u003c\/b\u003e: Programmed Cell Death Protein 1 Ligand 1\u003c\/p\u003e\u003cp\u003e\u003cb\u003eAlternative Names\u003c\/b\u003e: CD274; PDCD1LG1; B7-H; B7H1; PD-L1; PDCD1L1; PDCD1-LG1; Programed Death Ligand 1\u003c\/p\u003e\u003cp\u003e\u003cb\u003eTarget Species\u003c\/b\u003e: Human\u003c\/p\u003e\u003cp\u003e\u003cb\u003eUniprot\u003c\/b\u003e: Q9NZQ7\u003c\/p\u003e\u003cp\u003e\u003cb\u003eGene ID\u003c\/b\u003e: 29126\u003c\/p\u003e\u003cp\u003e\u003cb\u003eFeatured Series\u003c\/b\u003e: SE kit\u003c\/p\u003e\u003cp\u003e\u003cb\u003eFeatured Series Function\u003c\/b\u003e: Detects protein (regular version)\u003c\/p\u003e\u003cp\u003e\u003cb\u003eSpecificity\u003c\/b\u003e: Reactive with Human PDL1 \/ Programmed Cell Death Protein 1 Ligand 1\u003c\/p\u003e\u003cp\u003e\u003cb\u003eMethod\u003c\/b\u003e: Colormetric\u003c\/p\u003e\u003cp\u003e\u003cb\u003eDetection principle\u003c\/b\u003e: Double-antibody Sandwich\u003c\/p\u003e\u003cp\u003e\u003cb\u003eDetection\nrange\u003c\/b\u003e: 0.156-10ng\/mL\u003c\/p\u003e\u003cp\u003e\u003cb\u003eSensitivity\u003c\/b\u003e: 0.056ng\/mL\u003c\/p\u003e\u003cp\u003e\u003cb\u003eAssay Time\u003c\/b\u003e: 3h\u003c\/p\u003e\u003cp\u003e\u003cb\u003eSample Size\u003c\/b\u003e: 100uL\u003c\/p\u003e\u003cp\u003e\u003cb\u003eRecommended\/Predicted\nSample Types\u003c\/b\u003e: Serum, Plasma, Tissue Homogenates and other Biological Fluids\u003c\/p\u003e\u003cp\u003e\u003cb\u003eAssay Precision\u003c\/b\u003e: Intra-Assay: CV\u0026lt;10%, Inter-Assay: CV\u0026lt;12%\u003c\/p\u003e\u003cp\u003e\u003cb\u003eReproducibility test menthod\u003c\/b\u003e: Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Programmed Cell Death Protein 1 Ligand 1 (PDL1) were tested 20 times on one plate, respectively.\nInter-assay Precision (Precision between assays): 3 samples with low, middle and high level Programmed Cell Death Protein 1 Ligand 1 (PDL1) were tested on 3 different plates, 8 replicates in each plate.\nCV(%) = SD\/meanX100\u003c\/p\u003e\u003cp\u003e\u003cb\u003eStorage\u003c\/b\u003e: 4°C for 1 month\/ -20°C for long-term(One year within shelf life)\u003c\/p\u003e\u003cp\u003e\u003cb\u003eShelf-life\u003c\/b\u003e: 12 months\u003c\/p\u003e\u003cp\u003e\u003cb\u003eSpecificity\u003c\/b\u003e: This assay has high sensitivity and excellent specificity for detection of Programmed Cell Death Protein 1 Ligand 1 (PDL1).\nNo significant cross-reactivity or interference between Programmed Cell Death Protein 1 Ligand 1 (PDL1) and analogues was observed.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eStability\u003c\/b\u003e: The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.\nTo minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eAssay procedure summary\u003c\/b\u003e: 1. Prepare all reagents, samples and standards;\n2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;\n3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;\n4. Aspirate and wash 3 times;\n5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;\n6. Aspirate and wash 5 times;\n7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;\n8. Add 50µL Stop Solution. Read at 450nm immediately.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eTest principle\u003c\/b\u003e: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Programmed Cell Death Protein 1 Ligand 1 (PDL1). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Programmed Cell Death Protein 1 Ligand 1 (PDL1). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Programmed Cell Death Protein 1 Ligand 1 (PDL1), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Programmed Cell Death Protein 1 Ligand 1 (PDL1) in the samples is then determined by comparing the O.D. of the samples to the standard curve.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eResearch Area\u003c\/b\u003e: Signal transduction;Tumor immunity;Infection immunity;Immune molecule;Autoimmunity;\u003c\/p\u003e\u003cp\u003e\u003cb\u003eReferences Citing This Product\u003c\/b\u003e: \u003ca href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3937742\/\"\u003eLevel of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications\u003c\/a\u003e\u003c\/p\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24732592\"\u003eHigh level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial.\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24816853\"\u003ePD‐L1 gene polymorphisms and low serum level of PD‐L1 protein are associated to type 1 diabetes in Chile\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26686046\"\u003eRatios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27039170\"\u003eHigh levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"http:\/\/link.springer.com\/article\/10.1007\/s00432-016-2184-6\"\u003eSerum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27737703\"\u003ePD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer\/T-cell lymphoma\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28212990\"\u003eHigh plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27780932\"\u003eSoluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predictssurvival in advanced biliary tract cancer patients treated with palliative chemotherapy.\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27105512\"\u003eHigh post-treatment serum levels of soluble programmed cell death ligand 1 predict earlyrelapse and poor prognosis in extranodal NK\/T cell lymphoma patients.\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27566569\"\u003eSoluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28349165\"\u003eProgrammed death-ligand 1 and its soluble form are highly expressed in nasal natural killer\/T-cell lymphoma: a potential rationale for immunotherapy.\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"http:\/\/www.nature.com\/leu\/journal\/v31\/n4\/full\/leu2016385a.html\"\u003eSoluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28207525\"\u003ePlasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy.\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27617656\"\u003eInverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5319514\/\"\u003ePlasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"https:\/\/www.atsjournals.org\/doi\/pdf\/10.1164\/ajrccm-conference.2018.197.1_MeetingAbstracts.A4693\"\u003eSoluble Programed Death Receptor 1 Ligand (sPD-L1) in Pleural Fluid of Patients with Malignant Pleural Mesothelioma (MPM)\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29859759\"\u003eSoluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29419471\"\u003eIncreased levels of soluble programmed death ligand 1 associate with malignancy in patients with dermatomyositis\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29698935\"\u003eHigh Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0165247818302463\"\u003eIncreased levels of soluble co-stimulatory molecule PD-L1 (B7-H1) in the plasma of viraemic HIV-1+ individuals\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"https:\/\/link.springer.com\/article\/10.1007\/s00432-018-2758-6\"\u003ePre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"https:\/\/link.springer.com\/article\/10.1245\/s10434-018-07112-x\"\u003eSoluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between …\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"https:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0212978\"\u003eClinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated …\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/aop\/ec-19-0210.xml\"\u003eElevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6668419\/\"\u003ePrognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31675543\/\"\u003eThe Clinical Significance of Soluble PD-1 and PD-L1 in Lung Cancer\u003c\/a\u003e\u003cp\u003e \u003c\/p\u003e","brand":"GeneBio Systems","offers":[{"title":"Default Title","offer_id":48696692244580,"sku":"SEA788Hu","price":897.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0558\/8588\/9636\/files\/no_image_default_image-jpeg_b09f502c-3e86-44c5-b2ea-cc2f6d79cd94.jpg?v=1783134294","url":"https:\/\/www.genebiosystems.com\/en-fr\/products\/pdl1-elisa-kit-for-human","provider":"GeneBio ","version":"1.0","type":"link"}